Stanford study reveals cure for type 1 diabetes in mice with blood cell and pancreatic islet transplant

Researchers at Universidade of Stanford announced results of a study that completely reversed type 1 diabetes in mice through a combined transplant of blood stem cells and pancreatic islets from immunologically incompatible donors. The experiment, conducted on Escola of Medicina of Essa approach aims to overcome the autoimmune attack that destroys insulin-producing cells in the pancreas.
The method involved the administration of anti-CD117 antibodies and low doses of radiation to prepare the animals’ bodies, followed by the transplantation of donor cells. Todos the nine mice with established type 1 diabetes regained normal insulin production and maintained stable blood glucose levels for at least six months, without complications such as rejection or graft-versus-host disease.
In preventative trials, 19 of 19 pre-diabetic mice avoided developing the disease after the procedure. The study was published in the journal The Journal of Clinical Investigation and highlights the potential for applications in humans, although challenges such as islet availability remain.
- Reversal of 100% of cases of established diabetes;
- Total prevention in animals at risk;
- No serious side effects observed.
Transplant preparation
The initial preparation used specific antibodies to deplete hostile immune cells in the recipient mice. Essa stage lasted a few hours and avoided the use of intensive chemotherapy, common in traditional transplants.
Minimal doses of radiation were applied to facilitate the integration of the donor cells. The researchers monitored the animals daily for precise adjustments.

Hybrid method in action
The transplant combined hematopoietic stem cells with pancreatic islets from the same donor. Essa strategy created a mixed chimerism, where the recipient’s immune system permanently incorporated elements from the donor.
The treated mice stabilized their blood glucose within 24 hours after the procedure. Nenhum animal required exogenous insulin during the observation period.
Researchers noted that the immune hybrid tolerated the islets without recurring autoimmune attacks. Análises histological tests confirmed the survival of the cells transplanted into the pancreas.
The process took about a week for complete stabilization. Equipes recorded minimal variations in hormonal levels, indicating successful endogenous regulation.
Results in animal models
All animals with chronic type 1 diabetes recovered full pancreatic function. Endogenous insulin levels increased by 80% in relation to baseline values, according to laboratory tests.
In pre-diabetic mice, the procedure prevented the destruction of beta cells in 100% of cases. Monitoramento after six months showed no recurrent hyperglycemia.
No signs of chronic inflammation or fibrosis were detected in the pancreatic tissues. The rats maintained normal weight and physical activity without additional interventions.
- Average increase in insulin: 80%;
- Prevention rate: 100%;
- Duration of euglycemia: more than 180 days.
Study leadership
Seung K. Kim, professor of developmental biology at Stanford, led the research alongside Preksha Bhagchandani. Kim emphasized the relevance of chimerism to autoimmune diseases.
The team included experts in immunology and endocrinology. Colaborações with the Centro of Pesquisa in Diabetes of Stanford accelerated preclinical testing.
The group tested variations of the protocol in subgroups of animals. Ajustes based on initial responses optimized the success rate to 100%.
Implications for future treatments
The technique could expand options for solid organ transplants in humans. Pesquisas in progress aims to generate islets in the laboratory from human pluripotent stem cells, resolving donor limitations.
Challenges include scaling to adult patients, where the human pancreas differs in complexity. Estudos initial clinicians plan to start in 2026, focusing on safety.
Alternatives such as islet encapsulation for extra protection are under evaluation. The hybrid approach could reduce infection risks associated with traditional immunosuppressants.
Immune reset provides the basis for therapies in other autoimmune conditions, such as lupus or multiple sclerosis. Global Equipes monitor data for regional adaptations.
Challenges in transitioning to humans
The number of islets from a single donor may not be sufficient for advanced cases of type 1 diabetes.
The human immune system has greater genetic variability, requiring extensive testing. Protocolos of low radiation needs validation in phase I trials.
Availability of compatible donors remains a logistical hurdle. Iniciativas for stem cell banks seek to mitigate this issue in medical centers.
Regulators like the FDA evaluate the protocol for accelerated approvals. Initial Participantes will be selected from patients with long-standing diabetes.
Parallel advances in therapies
Other recent studies explore gene editing to protect transplanted islets. Técnicas of CRISPR aims to edit autoimmune genes directly in beta cells.
Implantable bioengineered devices maintain viable islets for months without replacement. Testes in primates show survival rates of 70% at one year.
Preventive vaccines for high-risk type 1 diabetes delay the onset by up to two years. Aprovações like teplizumab in 2022 pave the way for hybrid combinations.
Chinese research with adipose stem cells demonstrates insulin independence in patients for 12 months. Colaborações international organizations accelerate data sharing.






